Novel Nitrile Peptidomimetics for Treating COVID-19

COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Ni...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2022-03, Vol.13 (3), p.330-331
Main Author: Chia, C. S. Brian
Format: Article
Language:English
Subjects:
Patent Highlight
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure–activity relationship of key inhibitors described in the patent WO 2021/250648 A1.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.2c00030